JOURNAL ARTICLE
Add like
Add dislike
Add to saved papers

Regulatory T-cell deficiency in rheumatic heart disease: a preliminary observational study.

BACKGROUND AND AIM OF THE STUDY: Autoimmunity plays an essential role in the pathogenesis of rheumatic heart disease (RHD). The CD4+CD25+ T cell (Tregs) is the chief regulator of autoimmunity, and is essential for the induction and maintenance of self-tolerance and prevention of autoimmunity. To date, the levels of Tregs in RHD have not been investigated. Hence, the study aim was to monitor levels of circulating Tregs in patients with RHD, and to determine whether these differ according to the extent of valvular involvement.

METHODS: A total of 100 adult patients with RHD and 50 age- and gender-matched controls were studied. Patients were subdivided according to the extent of left-sided valvular involvement. Those with echocardiographic evidence only of significant mitral valve disease were enrolled in the univalvular group, while those with significant involvement of both mitral and aortic valves were allocated to the multivalvular group. Levels of circulating Tregs were determined using flow cytometry.

RESULTS: Levels of Tregs in total lymphocytes and CD4+ T lymphocytes were significantly lower in RHD patients than in controls (3.55 +/- 2.28% versus 5.76 +/- 4.2%; p < 0.001, and 14.4 +/- 9.4% versus 18.6 +/- 10.4%; p = 0.011, respectively). Within the study group, the proportion of Tregs to total and CD4+ T lymphocytes was significantly lower in patients with multivalvular than with univalvular disease (2.7 +/- 1.52% versus 4.41 +/- 2.58%; p = 0.001 and 11.5 +/- 8.5% versus 17.4 +/- 9.4%; p = 0.001, respectively).

CONCLUSION: The present study was the first to demonstrate a significant deficiency of circulating Tregs in RHD patients; notably, the reduction was greater in patients with multivalvular than with univalvular involvement.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app